EU Committee Backs Collective Drug Price Talks, Early-Warning System For Shortages
A report beefing up the proposals contained in the European Commission’s Pharmaceutical Strategy has been approved by an influential parliamentary committee that wants to see a “stable, updated and safety-centered regulatory system” and an "autonomous and resilient" pharmaceutical industry.
You may also be interested in...
As discussions continue over the European Commission’s plans to overhaul the EU pharmaceutical legislation, the R&D-based pharma industry body EFPIA says that any new pharma policy framework will need to be stable, fast, effective and globally competitive.
The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.